Novo-Nordisk stock gains a fresh DKK 15 billion buyback signal

Published on 10/05/2026 at 21:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo-Nordisk stock gains a fresh buyback signal as the company reports DKK 10.2 billion of repurchases through October 2. Q2 adjusted sales rose 7 percent.

Pop-Art-Insulin-Pen im Halftone-Raster, knallbunte Primärfarben, Comic-Stil — Novo Nordisk A/S (DK0062498333): stilisierter Insulin-Pen im Pop-Art-Halftone-Raster mit knallbunten Primärfarben und Comic-Aktionslinien, Illustration mit AI erstellt.

Novo-Nordisk stock is backed by a DKK 15 billion repurchase program announced on October 5, 2026, while the company had already bought 36,604,179 B shares for DKK 10.2 billion by October 2. The latest Q2 figures show adjusted sales of DKK 78,488 million, up 7 percent at constant exchange rates.

Buyback reaches DKK 10.2 billion

According to GlobeNewswire on October 5, 2026, Novo Nordisk can repurchase B shares for up to DKK 15 billion over the 12-month program that began February 4, 2026. The current tranche allows purchases of up to DKK 11.2 billion through February 1, 2027.

The company reported 50,644,876 B shares held as treasury shares, equal to 1.1 percent of share capital, after transactions through October 2. The average purchase price for the cumulative program stood at DKK 279.95 per B share, with transaction value of DKK 10,247,270,869.

Q2 sales rise as margins face pressure

In the Q2 2026 announcement, Globenewswire reported adjusted operating profit of DKK 33,389 million, up 11 percent at constant exchange rates. Adjusted sales and adjusted operating profit both exclude the non-recurring impact of US 340B provision reversals and a DKK 6.3 billion non-cash impairment charge affected reported Q2 profit.

The 2026 outlook remains a measured growth signal: adjusted sales growth and adjusted operating profit growth are both expected at 0 percent to minus 6 percent at constant exchange rates. The prior May outlook for both measures was minus 4 percent to minus 12 percent, so the new range represents a narrower decline outlook.

Analyst targets stay above ADR price

For the NYSE ADR, Gekko lists a Hold consensus from 7 firms, including 6 Hold ratings and 1 Sell rating. Its average 12-month target is USD 45.99, compared with the USD 37.32 October 2 ADR close, placing the target 23.2 percent above that close.

The companys next scheduled checkpoint is also concrete. Novo Nordisk will announce its first three quarters of 2026 results on November 4, 2026, at 7:30 a.m. CEST, according to its financial results calendar.

Buyback adds support to strategy

Novo Nordisk is using capital returns while investing in its GLP-1 portfolio and broader pipeline. The combination of 7 percent adjusted sales growth in Q2 2026 and a 0 percent to minus 6 percent full-year outlook leaves the November report as the next test of whether volume growth can offset pricing and investment pressure.